India Neurology Clinical Trials Market Report 2022 to 2030

India Neurology Clinical Trials Market Analysis

$ 3999

India's Neurology Clinical Trials market is projected to grow from $95.1 Mn in 2022 to $182.7 Mn by 2030, registering a CAGR of 8.5% during the forecast period of 2022-30. The market will be driven by the high prevalence of neurological disorders and the low cost of conducting clinical trials in India. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis, Sun Pharmaceutical Industries & Cadila Healthcare.

ID: IN10INCT005 CATEGORY: Clinical Trials GEOGRAPHY: India AUTHOR: Vidhi Upadhyay

Buy Now

India Neurology Clinical Trials Market Executive Summary

India's Neurology Clinical Trials market is projected to grow from $95.1 Mn in 2022 to $182.7 Mn by 2030, registering a CAGR of 8.5% during the forecast period of 2022-30. Every year, it is believed that 30 million Indians suffer from severe neurological problems. Epilepsy affects 6-8 million individuals, strokes affect 1-2 million people, and headaches affect 10-12 million people. Additionally, epilepsy is the leading cause of neuropsychiatric deaths. Stroke is one of India's top five major causes of mortality, with the World Health Organization reporting 1.5 million instances per year, with at least one-third being handicapped. By 2050, India and China will account for 80 percent of all stroke cases worldwide. According to the data, there is a growing need in India for clinical trials in the area.

The neurology clinical trials industry in India is rapidly expanding. With a population of over 1.3 billion people, India offers a big pool of prospective participants for clinical trials in the neurology field. Moreover, the nation has a well-established healthcare system as well as a high number of skilled healthcare workers, such as doctors and clinical research specialists. This has made India a desirable destination for conducting clinical trials in the field of neurology.

In November 2022, Hyderabad-based Suven Life Sciences (Suven) announced it had begun the randomization of the first patient in the Phase 3 worldwide clinical trial of its medication Masupirdine for the treatment of agitation in Alzheimer's dementia patients. Also, other trials are being carried out by companies such as Teva Pharmaceutical Industries, Biogen Idec and others mainly for conditions such as multiple sclerosis & Alzheimer's.

India Neurology Clinical Trials Market

Market Dynamics

Market Growth Drivers

The Indian government has developed clinical trial standards and a simplified clearance procedure for new studies. In addition, the government has formed the Central Drugs Standard Control Organization (CDSCO), which is in charge of ensuring that clinical trials in the country are done ethically and in accordance with international standards. India's healthcare system is well-developed, and there is a rising pool of skilled healthcare workers, including doctors and clinical research specialists. This facilitates pharmaceutical firms conducting clinical trials in the nation. Moreover, clinical trials in India might be less expensive than in other nations. The cost of performing clinical trials in India is cheaper than in many other nations, making it an appealing site for pharmaceutical firms conducting clinical studies.

Market Restraints

Although India has a well-developed healthcare system, there may be inadequate infrastructure in certain localities, making clinical trials challenging to execute in specific areas. There may be cultural variations between India and other nations that impact clinical trial conduct. To meet these variances, pharmaceutical firms may need to adapt their trial techniques. Concerns have been raised in India concerning intellectual property difficulties, which may deter some pharmaceutical firms from doing clinical trials there.

Competitive Landscape

Key Players

Pfizer
Novartis
Eli Lilly and Company
Sanofi
GlaxoSmithKline (GSK)
Merck & Co.
Sun Pharmaceutical Industries (IND)
Lupin Pharmaceuticals (IND)
Dr. Reddy's Laboratories (IND)
Cadila Healthcare (IND)
Suven Life Sciences (IND)

Notable Insights

November 2022, Hyderabad-based Suven Life Sciences (Suven) announced it had begun randomization of the first patient in Phase 3 worldwide clinical trial of its medication Masupirdine for the treatment of agitation in Alzheimer's dementia patients

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Neurology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.